Albireo Pharma, Inc.

Albireo Pharma, Inc. (NASDAQ: ALBO) is a biopharmaceutical business in the commercial stage. The company's primary emphasis is on developing and commercializing bile acid modulators to treat orphan paediatric liver illnesses and other liver and gastrointestinal diseases and disorders. Its medication, Bylvay, is approved in Europe to treat pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) aged three months or older.

Key Highlights

• The company reported YoY growth of 388.43% in total revenue to USD 40.58 million in FY21 (ended December 31, 2021) compared to USD 8.31 million in FY20.
• ALBO’s net loss reduced to USD 34.03 million in FY21 from USD 107.63 million in FY20.
• As of December 31, 2021, the company had cash and cash equivalents of USD 248.11 million and total debt of USD 10.00 million.
• Its ROE was -19.1% in FY21 vs. the industry median of -27.7%.
• ALBO’s net margin for FY21 was -83.9%, lower than the industry median of -118.6%.
• On March 29, 2022, ALBO reported  that patient enrolment in the ASSERT project, a Phase 3 pivotal trial of Bylvay (odevixibat) in patients with Alagille syndrome, had completed (ALGS). Topline findings are expected by the end of the year, in line with expectations, and with a total of 52 patients enrolled, compared to a target of 45.
• Stock is currently trading above its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bullish indicator.
• The stock is leaning towards the higher end of its 52-week range of USD 20.30 to USD 37.86.

Conclusion: Considering the company’s growth in topline, reduction in net losses, technical indicators, and associated risks. We recommend a "Watch" rating on the stock at the closing price of USD 35.57, up 2.77%, as of April 19, 2022.

Technical Price Chart (April 19, 2022). Source: REFINITIV, Analysis by Kalkine Group

Technical Analysis Summary:

*Closing price as of April 19, 2022

Investors can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.

Technical Indicators Defined: -

Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.

Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.

Note 1: The reference data in this report has been partly sourced from REFINITIV.  

Note 2: Investment decision should be made depending on the investors' appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above. 

Note 3: The report publishing date is as per the Pacific Time Zone.

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.